Cited by 127Retinal Development and DisordersVirus-based gene therapy researchRetinal Diseases and Treatments

Gene therapy and genome surgery in the retina

Open access
DiCarlo, James E., Mahajan, Vinit B., Tsang, Stephen H.·2018·Journal of Clinical Investigation

Abstract

Precision medicine seeks to treat disease with molecular specificity. Advances in genome sequence analysis, gene delivery, and genome surgery have allowed clinician-scientists to treat genetic conditions at the level of their pathology. As a result, progress in treating retinal disease using genetic tools has advanced tremendously over the past several decades. Breakthroughs in gene delivery vectors, both viral and nonviral, have allowed the delivery of genetic payloads in preclinical models of retinal disorders and have paved the way for numerous successful clinical trials. Moreover, the adaptation of CRISPR-Cas systems for genome engineering have enabled the correction of both recessive and dominant pathogenic alleles, expanding the disease-modifying power of gene therapies. Here, we highlight the translational progress of gene therapy and genome editing of several retinal disorders, including RPE65-, CEP290-, and GUY2D-associated Leber congenital amaurosis, as well as choroideremia, achromatopsia, Mer tyrosine kinase- (MERTK-) and RPGR X-linked retinitis pigmentosa, Usher syndrome, neovascular age-related macular degeneration, X-linked retinoschisis, Stargardt disease, and Leber hereditary optic neuropathy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci120429

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The non-pathogenic equine infectious anemia virus (EIAV) is in clinical trials to treat Usher Syndrome and Stargardt disease.

    “Currently, the non-pathogenic equine infectious anemia virus (EIAV) is in clinical trials to treat Usher Syndrome [50] and Stargardt disease [51,52].”

    From The Ocular Gene Delivery Landscape (2021) · cites this paper as [50]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

6 of the 181 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Coffin JM, Hughes SH, Varmus HE, eds. Retroviruses. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press; 1997. https://www.ncbi.nlm.nih.gov/books/ NBK19376/. Accessed April 19, 2018.
  2. Garanto A, et al. In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery. Hum Mol Genet. 2016;25(12):2552-2563.

Cited by

Sorted by citations

Authors
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H.
Affiliations
  • NewYork–Presbyterian Hospital (US)
  • VA Palo Alto Health Care System (US)
Corresponding author
Tsang, Stephen H.
Venue
Journal of Clinical Investigation
Published
2018-06-01
Volume
128
Issue
6
Pages
2177-2188
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2807488219
Cited by
127
References
181
Citations by year
2026: 4 · 2025: 7 · 2024: 9 · 2023: 17 · 2022: 15 · 2021: 27 · 2020: 24 · 2019: 14 · 2018: 9 · 2017: 1
FWCI
1.81
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5P30EY019007,R01EY018213,R01EY024698,R01EY026682,R21AG050437)
  • National Cancer Institute (5P30CA013696)
  • Schneeweiss Stem Cell Fund, New York State (C029572)
  • Foundation Fighting Blindness New York Regional Research Center Grant (C-NY05-0705-0312)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
gene therapy, genome editing, retinal disease, CRISPR-Cas, gene delivery vectors, Leber congenital amaurosis, choroideremia, achromatopsia, retinitis pigmentosa, Usher syndrome, neovascular age-related macular degeneration, X-linked retinoschisis, Stargardt disease, Leber's hereditary optic neuropathy, RPE65, CEP290, MERTK, RPGR, precision medicine
MeSH terms
Gene Editing, Animals, Humans, Retinal Diseases, Genetic Therapy, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review